TY - JOUR
T1 - Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma
AU - Antoun, Sami
AU - Lanoy, Emilie
AU - Albiges-Sauvin, Laurence
AU - Escudier, Bernard
N1 - Funding Information:
L Albiges-Sauvin has a consultant and advisory role at Novartis and has received research funding from Novartis. B Escudier has a consultant and
PY - 2014/3/1
Y1 - 2014/3/1
N2 - According to computed tomography image analysis, skeletal muscle (SM) and adipose tissue areas vary widely in patients with the same body mass index or the same body surface area. Body composition variables such as SM mass, SM density and subcutaneous and visceral adipose tissue have shown value as potential independent predictive factors for survival in cancer patients, although data for patients with renal cell carcinoma (RCC) undergoing targeted therapy remain relatively scarce. Confirmation of their prognostic value is required before they can be considered useful adjuncts to conventional predictive models of survival in RCC patients. In addition, variability in SM mass might affect drug toxicity, with patients with a low rather than high SM mass being at a higher risk of toxicity. A dose tailored to the individual patient's SM mass might lower toxicity in RCC patients, enable completion of the treatment plan and thus impact favorably on treatment effectiveness.
AB - According to computed tomography image analysis, skeletal muscle (SM) and adipose tissue areas vary widely in patients with the same body mass index or the same body surface area. Body composition variables such as SM mass, SM density and subcutaneous and visceral adipose tissue have shown value as potential independent predictive factors for survival in cancer patients, although data for patients with renal cell carcinoma (RCC) undergoing targeted therapy remain relatively scarce. Confirmation of their prognostic value is required before they can be considered useful adjuncts to conventional predictive models of survival in RCC patients. In addition, variability in SM mass might affect drug toxicity, with patients with a low rather than high SM mass being at a higher risk of toxicity. A dose tailored to the individual patient's SM mass might lower toxicity in RCC patients, enable completion of the treatment plan and thus impact favorably on treatment effectiveness.
KW - body composition
KW - chemotherapy toxicity
KW - muscle anabolism
KW - prognosis
KW - sarcopenia
KW - skeletal muscle density
KW - skeletal muscle mass
KW - subcutaneous adipose tissue
KW - targeted therapy
KW - visceral adipose tissue
UR - http://www.scopus.com/inward/record.url?scp=84896738071&partnerID=8YFLogxK
U2 - 10.1586/14737140.2013.866040
DO - 10.1586/14737140.2013.866040
M3 - Review article
C2 - 24405390
AN - SCOPUS:84896738071
SN - 1473-7140
VL - 14
SP - 279
EP - 288
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
IS - 3
ER -